Blog Posts - European Medicines Agency (ema)

In The Shadow Of Recent Announcement About Diabetes Drug Jardiance Medical Study Results There Lingers Safety Concerns For SGLT-2 Inhibitors

As With Invokana and Farxiga, Jardiance Is Subject Of Several Drug Regulatory Agency Investigations About Ketoacidosis And Other Side Effects (Posted by Tom Lamb at Jardiance is part of the Sodium-Glucose Co-Transporter-2 (SGLT-2...
by Drug Injury Watch on Aug 21, 2015

Invokana Lawsuits Are Expected To Be Filed While FDA And Other Drug Regulators Investigate Side Effects Reports

Drug Injury Lawyers Also See Possible Farxiga And Jardiance Cases For Patients Who Have Ketoacidosis, Kidney Failure, Stroke, Or Heart Attack (Posted by Tom Lamb at With there being a growing number of Type 2 diabetes patients in...
by Drug Injury Watch on Jul 2, 2015

Various Drug Safety Issues Continue To Be Associated With Novartis Multiple Sclerosis (MS) Medication Gilenya

ISMP QuarterWatch Report From 2014 States Adverse Events Reports Show That Gilenya Cardiac Risks "were neither rare nor hypothetical" (Posted by Tom Lamb at The safety profile for the Novartis drug Gilenya (fingolimod)...
by Drug Injury Watch on Feb 16, 2015

Xolair Is Associated With Higher Than Expected Reporting Of Arterial Thrombotic Events Such As Strokes And Cardiovascular Deaths

While European Drug Regulators Have Been Concerned About This Aspect Of Xolair Safety, FDA Has No Warning About Arteriothrombotic Risks Of Xolair (Posted by Tom Lamb at In September 2014 the FDA issued an update about its safety...
by Drug Injury Watch on Dec 26, 2014

European Medicines Agency (EMA) Committee Recommends Further Restrictions On Use Of Depakote / Depakene / Depacon By Women Of Childbearing Age

Cites Higher Risks Of Neural Tube Defects Like Spina Bifida, Hypospadias, And Other Birth Defects As Well As Increased Risk Of Autism Spectrum Disorder (Posted by Tom Lamb at More restrictions of the use of valproate drugs -- suc...
by Drug Injury Watch on Oct 14, 2014

Trending Topics